News NICE guidance calls for quicker diagnosis of PMOS Women with polyendocrine metabolic ovarian syndrome (PMOS) should be diagnosed sooner and be offered an annual review, according to new NICE guidance.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.